What is Adcendo?
Adcendo operates within the dynamic life sciences sector, specializing in the advancement of targeted cancer therapies through innovative antibody-based platforms. The company's core focus lies in developing antibody-drug conjugate (ADC) therapies, a precision medicine approach that combines the specificity of antibodies with the potency of cytotoxic drugs to selectively target cancer cells. By leveraging expertise in biology, chemistry, and clinical development, Adcendo aims to address critical unmet medical needs in oncology. The company actively collaborates with scientific, clinical, and industry partners to accelerate its research and development pipeline, emphasizing innovation in drug design and precision-based treatment strategies.
How much funding has Adcendo raised?
Adcendo has raised a total of $316M across 3 funding rounds:
Series A
$106M
Series B
$135M
Series C
$75M
Series A (2024): $106M with participation from Novo Holdings, Gilde Healthcare, and Pontifax
Series B (2024): $135M led by Novo Holdings, TCG Crossover, and Logos Capital Partners Sa rl
Series C (2026): $75M supported by Jeito, Glide Healthcare Pvt, Vida Ventures, Logos Capital Partners Sa rl, Bpifrance, Venrock, RA Capital Management, OrbiMed, and Danish Export and Investment Fund
Key Investors in Adcendo
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999 and headquartered in Hellerup, Denmark, focusing on investments within the life sciences sector.
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm dedicated to advancing disruptive medicines, aiming to invest in breakthrough therapies with the potential to transform healthcare, particularly within the pharmaceutical and biotechnology sectors.
Logos Capital Partners Sa rl
Logos Capital Partners Sa rl operates within the Finance industry, headquartered in Cap, Luxembourg, and is involved in investment activities.
What's next for Adcendo?
With substantial enterprise-level backing, Adcendo is strategically positioned to accelerate the development and clinical progression of its ADC pipeline. The recent major strategic investment signals a pivotal phase for the company, likely enabling expansion of its research initiatives, advancement of lead candidates into later-stage clinical trials, and potential scaling of its operational capabilities. This capital will be instrumental in navigating the complex regulatory pathways and further solidifying its market presence in the competitive oncology landscape. The company's trajectory suggests a strong focus on translating its innovative therapeutic platforms into tangible patient benefits.
See full Adcendo company page
